Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 4 of 382 rows for Antipsychotics (harms / discontinuation). One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Antipsychotics (harms / discontinuation) Medicines | Treatment |
Benefit
whyDirection is for STOPPING the antipsychotic: discontinuers were hospitalised less than matched continuers. |
Hospitalisation, pneumonia and urinary tract infection | cohort study | 4,222 | All-cause hospitalisation HR 0.83 (95% CI 0.72-0.96); pneumonia hospitalisation HR 0.51 (0.29-0.90) |
Alzheimer's Research & Therapy
2026 ✓ Peer-reviewed PMID 42410659 |
| Antipsychotics (harms / discontinuation) Medicines | Treatment |
Benefit
whyDirection is for discontinuation: tapering after 12 weeks lowered the 24-month absolute risk of delirium and fracture versus continuing, with no difference in stroke, pneumonia or death. Results were similar for abrupt discontinuation and after 24 weeks. |
24-month risk of delirium, fracture, stroke, pneumonia and death after tapering or stopping antipsychotics versus continuing | cohort study | 24,822 | Compared with continuation after 12 weeks of treatment, estimated risks of delirium and fracture under the tapering strategy corresponded to 24-month ARDs of -2·46% (95% CI -4·10 to -1·27) and -2·80% (-4·14 to -1·29), respectively. Estimated risks for stroke, pneumonia, and all-cause mortality were similar between strategies |
The lancet. Healthy longevity
2026 ✓ Peer-reviewed PMID 42302797 |
| Antipsychotics (harms / discontinuation) Medicines | Treatment | Harm | 180-day mortality | case-control study | 139,103 | 180-day mortality HR 1.41 (95% CI 1.38-1.44) for benzodiazepines; HR 1.16 (95% CI 1.12-1.20) for antipsychotics |
JAMA Network Open
2025 ✓ Peer-reviewed PMID 41085983 |
| Antipsychotics (harms / discontinuation) Medicines | Treatment |
Harm
whyWider range of harms than regulatory alerts had flagged, with the highest risks soon after starting. No increase in ventricular arrhythmia. |
Stroke, pneumonia, venous thromboembolism, MI, heart failure, fracture, acute kidney injury | cohort study | 173,910 | Pneumonia HR 2.19 (95% CI 2.10-2.28); stroke HR 1.61 (1.52-1.71); absolute 90-day pneumonia risk difference 2.99% |
BMJ
2024 ✓ Peer-reviewed PMID 38631737 |
Last updated